Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population

Bioconjugate Chemistry
Halli BenasuttiDmitri Simberg

Abstract

Opsonization (coating) of nanoparticles with complement C3 component is an important mechanism that triggers immune clearance and downstream anaphylactic and proinflammatory responses. The variability of complement C3 binding to nanoparticles in the general population has not been studied. We examined complement C3 binding to dextran superparamagnetic iron oxide nanoparticles (superparamagnetic iron oxide nanoworms, SPIO NWs, 58 and 110 nm) and clinically approved nanoparticles (carboxymethyl dextran iron oxide ferumoxytol (Feraheme, 28 nm), highly PEGylated liposomal doxorubicin (LipoDox, 88 nm), and minimally PEGylated liposomal irinotecan (Onivyde, 120 nm)) in sera from healthy human individuals. SPIO NWs had the highest variation in C3 binding (n = 47) between subjects, with a 15-30 fold range in levels of C3. LipoDox (n = 12) and Feraheme (n = 18) had the lowest levels of variation between subjects (an approximately 1.5-fold range), whereas Onivyde (n = 18) had intermediate between-subject variation (2-fold range). There was no statistical difference between males and females and no correlation with age. There was a significant correlation in complement response between small and large SPIO NWs, which are similar structura...Continue Reading

References

Aug 1, 1990·The Journal of Experimental Medicine·B HeymanT Kinoshita
Jan 1, 1989·Cold Spring Harbor Symposia on Quantitative Biology·C A Janeway
Aug 13, 1982·Journal of Immunological Methods·R S Molday, D MacKenzie
Jan 13, 2004·Methods in Enzymology·Janos SzebeniCarl R Alving
Feb 1, 2005·Analytical Chemistry·Fred ReynoldsLee Josephson
Mar 12, 2005·Science·Albert O EdwardsLindsay A Farrer
Mar 18, 2005·Annual Review of Immunology·P R TaylorS Gordon
Mar 15, 2006·Cell·Karim Y HelmyMenno van Lookeren Campagne
Oct 27, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S Moein MoghimiJanos Szebeni
Jul 21, 2007·The American Journal of Pathology·Maciej M Markiewski, John D Lambris
Apr 7, 2009·Nano Letters·Steven D PerraultWarren C W Chan
Jul 16, 2009·Inflammation & Allergy Drug Targets·Qi PengWuding Zhou
Nov 17, 2009·Journal of Immunological Methods·P J Lachmann
Dec 17, 2009·Cell Research·Jason R Dunkelberger, Wen-Chao Song
Jan 8, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Martin Bjerregård PedersenThomas Vorup-Jensen
Jan 9, 2010·Journal of Biomedical Nanotechnology·Alina J AndersenS Moein Moghimi
Aug 20, 2010·Nature Immunology·Daniel RicklinJohn D Lambris
Sep 28, 2010·Molecular Cancer Research : MCR·Martin J RutkowskiAndrew T Parsa
Nov 5, 2010·The Journal of Biological Chemistry·Christine T N PhamDennis E Hourcade
May 11, 2011·Proceedings of the National Academy of Sciences of the United States of America·Meike HeurichClaire L Harris
Apr 10, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yechezkel Barenholz
Jul 4, 2012·Trends in Immunology·Claire L HarrisB Paul Morgan
Mar 19, 2013·Nanomedicine : Nanotechnology, Biology, and Medicine·S Moein Moghimi, Z Shadi Farhangrazi
Aug 1, 2013·Proceedings of the National Academy of Sciences of the United States of America·Martín AlcorloOscar Llorca
Nov 12, 2013·Nanomedicine : Nanotechnology, Biology, and Medicine·Christine T N PhamDennis E Hourcade
Apr 22, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·S M Moghimi
Apr 22, 2014·Trends in Immunology·Rahul Satija, Alex K Shalek
Mar 4, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Min H KangC Patrick Reynolds
Nov 27, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Peter P WibroeS Moein Moghimi
Dec 20, 2016·Nature Nanotechnology·Fangfang ChenDmitri Simberg

❮ Previous
Next ❯

Citations

Jan 24, 2018·Journal of Personalized Medicine·Stuart P AtkinsonMaría J Vicent
Jul 14, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Barry W NeunMarina A Dobrovolskaia
May 12, 2020·Advanced Drug Delivery Reviews·S Moein MoghimiZ Shadi Farhangrazi
Aug 29, 2018·Advanced Drug Delivery Reviews·Hamideh ParhizVladimir R Muzykantov
Jun 15, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·B Halamoda-KenzaouiF Caputo
Jul 11, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Christopher N SubasicLisa M Kaminskas
Aug 8, 2021·Acta Biomaterialia·Natalia OnishchenkoElena Vodovozova
Dec 6, 2018·ACS Nano·Weston J SmithDmitri Simberg
Apr 12, 2019·Journal of Controlled Release : Official Journal of the Controlled Release Society·Geoffrey GiffordDmitri Simberg
Jan 20, 2022·Journal of Biomedical Materials Research. Part a·Edson J ComparettiValtencir Zucolotto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.